Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash from Investing Activities (2020 - 2025)

Bioventus (BVS) has disclosed Cash from Investing Activities for 6 consecutive years, with -$580000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 102.41% year-over-year to -$580000.0, compared with a TTM value of -$3.2 million through Dec 2025, down 114.14%, and an annual FY2025 reading of -$3.2 million, down 114.14% over the prior year.
  • Cash from Investing Activities was -$580000.0 for Q4 2025 at Bioventus, down from -$473000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $101.4 million in Q4 2022 and bottomed at -$221.3 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is -$12.4 million, with a median of -$1.2 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities crashed 12832.67% in 2021, then skyrocketed 4178.51% in 2024.
  • Year by year, Cash from Investing Activities stood at -$221.3 million in 2021, then soared by 145.84% to $101.4 million in 2022, then plummeted by 100.58% to -$591000.0 in 2023, then surged by 4178.51% to $24.1 million in 2024, then plummeted by 102.41% to -$580000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for BVS at -$580000.0 in Q4 2025, -$473000.0 in Q3 2025, and -$1.4 million in Q2 2025.